Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer

Ansinelli, Hayden; Gay, Chris; Nguyen, Steven; Morrison, C.; Robbins, Jared R.

doi:10.1016/j.jncc.2022.11.006

Cited by 2 publications

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is especially important in the group of patients with HPV-associated oropharyngeal cancer, who have longer overall and disease-free survival. Different strategies have been developed with the aim of reducing adverse effects [ 22 ] among which are the use of advanced radiotherapy techniques and the use of less invasive surgical techniques such as transoral laser microsurgery [ 23 , 24 ] or transoral robotic surgery [ 25 ] in early stage oropharyngeal cancer. At the international level, there has been a new development of these less invasive techniques [ 26 – 28 ] with good oncologic results in a long series of one centre [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Epidemiological and clinical description of patients with oropharyngeal cancer treated in a public oncology referral hospital in Chile

Carvajal V,

Cardemil,

Vásquez

et al. 2024

ecancer Journal

View full text Add to dashboard Cite

Introduction The incidence of squamous carcinoma of the oropharynx (OPSCC) has presented an increase worldwide, a fact that occurs along with a phenomenon of epidemiological transition, whose pathogenesis is linked to human papilloma virus (HPV) in a significant part of the cases. Published evidence at the Latin American level is scarce. The present study aims to evaluate the epidemiological and clinical characteristics of patients with oropharyngeal cancer treated in a public oncology reference centre in Chile. Methodology A cross-sectional study was carried out. Patients with histological confirmation of OPSCC aged 18 years or older, referred to the National Cancer Institute of Chile between 2012 and 2023 were included. The association with HPV was determined by immunohistochemistry for p16. Results 178 patients were analysed, most of them in locoregionally advanced stages involving the palatine tonsil. Seventy-seven percent were male, with a median age of 60 years. Sixty-seven percent of patients were positive for p16, with a progressive increase to 85% in the last 2 years of the study. The p16(+) patients were younger and had fewer classical risk factors. Primary treatment was radiotherapy in 94% of patients. Conclusion The epidemiological profile of patients with OPSCC treated in a Chilean public oncology referral centre reflects the epidemiological transition observed in developed countries. This change justifies the need to adapt health policies and conduct research that considers the characteristics of this new epidemiological profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiological and clinical description of patients with oropharyngeal cancer treated in a public oncology referral hospital in Chile

Carvajal V,

Cardemil,

Vásquez

et al. 2024

ecancer Journal

View full text Add to dashboard Cite

show abstract

IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV‐related and HPV‐unrelated disease

Sjöblom,

Jouhi,

Laakkonen

et al. 2024

APMIS

View full text Add to dashboard Cite

Biomarkers are not broadly used in the management of head and neck cancers (HNCs). Biomarkers have been beneficial in the management of other cancers, however, not in HNCs. Therefore, we observed the immunopositivity of a novel biomarker called immunoglobulin superfamily member 3 (IGSF3) in tumor tissues in HPV‐related and HPV‐unrelated OPSCC. Two patient cohorts (C1 and C2) from separate time periods were available for this study (total N = 282). Both consisted of OPSCC patients treated at the Helsinki University Hospital (HUS, Helsinki, Finland) during 2000–2016. For HPV determination, HPV mRNA in situ hybridization was used. Immunohistochemistry was used to assess IGSF3 immunopositivity in cancer tissues. Overall survival (OS) was used as endpoint in the statistical analysis. In C1, stronger immunopositivity of IGSF3 in tumor‐infiltrating lymphocytes (TILs) correlated with favorable OS (p = 0.005). Stronger IGSF3 immunopositivity in tumor cells (TCs) was associated with HPV negativity (p = 0.017). Stronger IGSF3 immunopositivity in TILs correlated with HPV positivity (p < 0.001). Elevated IGSF3 immunopositivity in TILs associates with HPV‐related tumors and may signify favorable prognosis. The immunopositivity of IGSF3 differs between HPV‐related and HPV‐unrelated OPSCC.

show abstract

Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer

Cited by 2 publications

References 85 publications

Epidemiological and clinical description of patients with oropharyngeal cancer treated in a public oncology referral hospital in Chile

Epidemiological and clinical description of patients with oropharyngeal cancer treated in a public oncology referral hospital in Chile

IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV‐related and HPV‐unrelated disease

Contact Info

Product

Resources

About